Controlled Substances Act, Mental Health, Food and Drug Administration (FDA)

Interest in Psilocybin Continues to “Mushroom” for Potential Mental Health Treatment

McGuireWoods LLP on 4/2/2024

Interest in the potential for psilocybin to be developed as a mental health treatment has continued to grow in recent months, due in part to recent activity by the U.S. Food and Drug Administration (FDA) and Drug Enforcement...more

Too Much Of A Good Thing?

Nelson Hardiman, LLP on 2/9/2024

F. Scott Fitzgerald famously declared that “Too much of anything is bad, but too much champagne is just right.” That may be true, but it now appears that it may have been “Special K” that proved the undoing of beloved actor...more

Five Key Regulatory Considerations for Virtual Ketamine Clinics

Goodwin on 11/17/2022

The off-label use of ketamine to treat anxiety, depression, and other behavioral health disorders —coupled with the COVID-19 telehealth era—has spurred the opening of virtual ketamine clinics nationwide. Some clinics offer a...more

Psilocybin May Brighten the Future for Depression Patients

Womble Bond Dickinson on 1/15/2021

The Struggle is Real - Over 17 million people in the United States are diagnosed with major depressive disorder (MDD). Antidepressants and psychotherapy are the leading forms of treatment; however, antidepressants are not...more

New Connecticut Law Allows Telemedicine Prescribing of Controlled Substances

Foley & Lardner LLP on 6/27/2018

Connecticut has taken another step towards expanding the meaningful use of telemedicine in connection with treatment of mental health and substance use disorders. SB 302, signed by Governor Dannel Malloy and effective July 1,...more

A&B Healthcare Week in Review

Alston & Bird on 4/1/2016

I. REGULATIONS, NOTICES, & GUIDANCE - On March 29, 2016, Centers for Medicare & Medicaid Services (CMS) issued a final rule entitled, “Medicaid and Children’s Health Insurance Programs: Mental Health Parity and...more